Small interventional synovial biopsy precision medicine study

      CD117 high pts n=15 = better response to IL17i or IL23i i

      Aurelie Najm AurelieRheumo

      1 week 1 day ago
      Small interventional synovial biopsy precision medicine study CD117 high pts n=15 = better response to IL17i or IL23i inhibition vs. TNFi w/ -DAPSA -13.5, -12.8 vs. -7.5 respectively Higher BL levels of tissue inflammation in Responders vs. NR More robust study design needed https://t.co/7jNff6lUJ6
      💊 Oral IL-23Ri for #PsA #PsO?

      ICONIC RCT (n=216):
      Yes! Icotrokinra improves pain & disease activity at week 16

      Nelly ZIADE 🍀 Nellziade

      1 week 1 day ago
      💊 Oral IL-23Ri for #PsA #PsO? ICONIC RCT (n=216): Yes! Icotrokinra improves pain & disease activity at week 16 #POS0052 #EULAR2026 @RheumNow https://t.co/PA4O36h02Y
      Nail #PsA, hard to treat and often overlooked. APEX trial: guselkumab achieved 43% ↓ in nail severity score (mNAPSI) v

      Jiha Lee JihaRheum

      1 week 1 day ago
      Nail #PsA, hard to treat and often overlooked. APEX trial: guselkumab achieved 43% ↓ in nail severity score (mNAPSI) vs 16% worsening on placebo at wk 24, plus PASI 100 in ~39% vs 11%. IL-23 inhibition delivering where pts often struggle most. @RheumNow #EULAR2026 POS0471
      💉 Risankizumab durable in #PsA?

      #POS0047 3 RCT n=964 KEEPsAKE
      Yes! ACR50 ~37% & MDA ~34% @w244
      no new safety sig

      Nelly ZIADE 🍀 Nellziade

      1 week 1 day ago
      💉 Risankizumab durable in #PsA? #POS0047 3 RCT n=964 KEEPsAKE Yes! ACR50 ~37% & MDA ~34% @w244 no new safety signals 💪 #EULAR2026 @RheumNow https://t.co/911Fi9vxfP
      🤔 GUS or IL-17i for #PsA?
      #POS0045: RW study:
      Both! ~76% persistence & similar effectiveness
      1141 pts @12mo #PsA

      Nelly ZIADE 🍀 Nellziade

      1 week 1 day ago
      🤔 GUS or IL-17i for #PsA? #POS0045: RW study: Both! ~76% persistence & similar effectiveness 1141 pts @12mo #PsABIOnd 🌍 #EULAR2026 @RheumNow https://t.co/PyuaH5B5V1
      Guselkumab in erosive #PsA: ACR20 68% vs 47% placebo, structural damage progression ↓ across subgroups regardless of s

      Jiha Lee JihaRheum

      1 week 1 day ago
      Guselkumab in erosive #PsA: ACR20 68% vs 47% placebo, structural damage progression ↓ across subgroups regardless of sex, BMI, MTX use, or joint counts. Highest inflammation and erosion burden? Biggest benefit. IL-23i holds up where it matters most. @RheumNow #EULAR2026 POS0480
      IL-23i vs IL-17i in PsABIOnd (n=1,141): 12mo persistence (~77%), joint/skin response, MDA, and PROs similar across both.

      Jiha Lee JihaRheum

      1 week 1 day ago
      IL-23i vs IL-17i in PsABIOnd (n=1,141): 12mo persistence (~77%), joint/skin response, MDA, and PROs similar across both. GUS matched IL-17i despite treating more biologic-experienced pts (15% vs 8% on 4th-line). GI AEs higher with IL-17i (11% vs 7%). @RheumNow #EULAR2026 POS0045
      What’s new in (WIN) PsA session. A preview of the BE BOLD study: Bimekizumab vs risankizumab on ACR50 in active #PsA

      Antoni Chan MD (Prof) synovialjoints

      1 week 1 day ago
      What’s new in (WIN) PsA session. A preview of the BE BOLD study: Bimekizumab vs risankizumab on ACR50 in active #PsA 49.1% vs 38.4% (p=0.008). The first head-to-head biologic trial to show joint superiority in PsA. Dual IL-17A/F blockade important. Abstr #LB0001 @RheumNow
      EULAR19.abstract.jpg (keep)
      EULAR 2026: Industry Press Releases
      1 week 2 days ago
      Pharmaceutical companies are presenting pivotal clinical trial results and key data analyses at the EULAR 2026 Congress (June 3–6, London). Below is a summary of their most important studies — many of which are registration-enabling or will directly shape treatment decisions in rheumatic diseases.

      Podcasts

      • EULAR 2026 Daily Podcast Day 4c

      Catch up on Conference Podcasts

      ×